Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epcoritamab - Genmab/AbbVie

Drug Profile

Epcoritamab - Genmab/AbbVie

Alternative Names: ABBV-GMAB-3013; Anti-CD3 anti-CD20 bispecific antibody - Genmab/AbbVie; Duobody-CD3-CD20; DuoBody-CD3xCD20; Epcoritamab-bysp; EPKINLY; GEN-3013; Tepkinly; TEPKINLY

Latest Information Update: 29 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer AbbVie; Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Preregistration Follicular lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Richter's syndrome

Most Recent Events

  • 27 Feb 2024 Epcoritamab receives priority review status for Follicular lymphoma (SC) in USA
  • 27 Feb 2024 FDA assigns PDUFA action date of 28/06/2024 for epcoritamab for Follicular lymphoma (SC)
  • 14 Feb 2024 Launched for Diffuse large B cell lymphoma (Second-line therapy or greater) in Japan (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top